No Data
No Data
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista (Sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults With Type 1 Diabetes and Chronic Kidney Disease
Express News | Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (Sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults With Type 1 Diabetes and Chronic Kidney Disease
Lexicon Diabetes Drug Sotagliflozin Fails to Win Support of FDA AdComm
Express News | FDA Advisory Panel Votes 11-3 Against Benefits of Lexicon Pharma's Sotagliflozin Outweigh Its Risks
Lexicon Pharmaceuticals Halted All Day as FDA Panel Reviews Zynquista
Trading Halt: Halted at 6:55:00 A.m. ET - Trading Halt: Halt News Pending
No Data
No Data